Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Business
  • Tech
  • Research
  • Regulatory
  • Events and Conferences
The Pharma Data
  • NewsPress Releases

Judo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney

  • The Pharma Data
  • October 28, 2024

Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA…

Read MoreJudo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney
  • News

Novartis Oral Fabhalta® Shows Sustained Benefits in One-Year Phase III C3G Trial

  • The Pharma Data
  • October 28, 2024

Novartis presented promising 12-month results from its Phase III APPEAR-C3G study at the 2024 American Society of Nephrology (ASN) Kidney Week. These findings show that patients with C3 glomerulopathy (C3G)…

Read MoreNovartis Oral Fabhalta® Shows Sustained Benefits in One-Year Phase III C3G Trial
  • Business

Astellas Updates on European Union Marketing Authorization Application for Avacincaptad Pegol (ACP)

  • The Pharma Data
  • October 28, 2024

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced the withdrawal of its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution…

Read MoreAstellas Updates on European Union Marketing Authorization Application for Avacincaptad Pegol (ACP)
  • Research

Biogen Shares Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024

  • The Pharma Data
  • October 28, 2024

Biogen Inc. (Nasdaq: BIIB) shared full results from its Phase 2 IGNAZ study on felzartamab, an investigational anti-CD38 monoclonal antibody, for IgA nephropathy (IgAN) treatment. Data revealed significant reductions in…

Read MoreBiogen Shares Positive Phase 2 Results for Felzartamab in IgA Nephropathy at ASN Kidney Week 2024
  • Regulatory

Dr. Reddy’s Recognized by Science Magazine as a Top 20 Global Pharma Employer for the Third Year in a Row

  • The Pharma Data
  • October 26, 2024

Dr. Reddy’s Laboratories Ltd. has been recognized as one of the top employers in the 2024 Top Biotech and Pharma Employers Survey conducted by Science magazine, marking the company’s third…

Read MoreDr. Reddy’s Recognized by Science Magazine as a Top 20 Global Pharma Employer for the Third Year in a Row
  • BusinessPress Releases

enGene Secures $60 Million in Private Placement Financing

  • The Pharma Data
  • October 26, 2024

enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has announced an agreement to sell 6,758,311 of its common shares at a price of $8.90 per share. This financing…

Read MoreenGene Secures $60 Million in Private Placement Financing
  • News

Felix Health Launches First National Menopause Show for Women in Perimenopause and Beyond

  • The Pharma Data
  • October 26, 2024

Felix Health, a virtual care provider dedicated to helping Canadians manage their everyday health needs, is excited to be the presenting sponsor of the National Menopause Show. Set to attract…

Read MoreFelix Health Launches First National Menopause Show for Women in Perimenopause and Beyond
Biogen
  • NewsResearch

LabGenomics USA Finalizes Acquisition of IMD CLIA Labs

  • The Pharma Data
  • October 26, 2024

LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, increasing its total number of CLIA-certified labs in the U.S. to four. This acquisition enhances LabGenomics’ strategic growth and…

Read MoreLabGenomics USA Finalizes Acquisition of IMD CLIA Labs
  • Press ReleasesRegulatory

Maze Therapeutics Announces Positive Phase 1 Data for MZE829 in Treating APOL1 Kidney Disease

  • The Pharma Data
  • October 26, 2024

Maze Therapeutics, a clinical-stage biopharmaceutical company focused on leveraging human genetics to create innovative small molecule precision medicines for common diseases, has announced promising results from the Phase 1 clinical…

Read MoreMaze Therapeutics Announces Positive Phase 1 Data for MZE829 in Treating APOL1 Kidney Disease
  • Research

BioHub Maryland Launches Biopharma Workforce Training Center in Montgomery County’s Life Sciences Corridor

  • The Pharma Data
  • October 26, 2024

BioHub Maryland, an initiative aimed at accelerating the life sciences sector in the state, officially opened its new biopharmaceutical workforce training center on October 24 at 9808 Medical Center Drive…

Read MoreBioHub Maryland Launches Biopharma Workforce Training Center in Montgomery County’s Life Sciences Corridor
  • Regulatory

Evecxia Therapeutics Successfully Completes Pre-IND Meeting with FDA on EVX-101 Development for Depression

  • The Pharma Data
  • October 26, 2024

Evecxia Therapeutics has announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) Division of Psychiatry, Office of Neuroscience, Center for…

Read MoreEvecxia Therapeutics Successfully Completes Pre-IND Meeting with FDA on EVX-101 Development for Depression
  • News

Lilly’s EBGLYSS™ Achieves Skin Clearance and Itch Relief in Atopic Dermatitis Patients

  • The Pharma Data
  • October 26, 2024

Eli Lilly and Company has reported encouraging findings regarding its treatment EBGLYSS, showing significant improvements in skin condition and itch relief for patients suffering from moderate-to-severe atopic dermatitis (eczema) who…

Read MoreLilly’s EBGLYSS™ Achieves Skin Clearance and Itch Relief in Atopic Dermatitis Patients
PrevNext
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • AngioDynamics Gains FDA IDE Approval for RELIEF BPH Study
  • Latin Clinical Trial Center Joins PhaseWell Research to Strengthen Clinical Research Access in Puerto Rico
  • Oligomerix Secures $1.9 Million NIH Phase II SBIR Fast-Track Grant to Advance OLX-07010 Toward Alzheimer’s Clinical Trials
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.